Home › Melanoom › Minnesota › Rochester
Melanoom klinische studies in Rochester, MN
16 studies voor Melanoom zoeken deelnemers op locaties in en rond Rochester (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruterenFase 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
RekruterenObservatieonderzoek
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RekruterenFase 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruterenObservatieonderzoek
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekruterenFase 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
RekruterenObservatieonderzoek
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RekruterenObservatieonderzoek
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Rekruteren
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RekruterenObservatieonderzoek
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
RekruterenFase 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekruterenFase 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekruterenFase 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruterenObservatieonderzoek
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RekruterenFase 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
RekruterenFase 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekruterenFase 1/2
- Mayo Clinic in Minnesota, Rochester
Melanoom studies in andere steden
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN33 studies
- Pittsburgh, PA31 studies
- Boston, MA26 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Durham, NC21 studies
- Atlanta, GA21 studies
- St. Louis, MO21 studies
- Salt Lake City, UT21 studies
Andere studies in Rochester
- Borstkanker42 studies
- Niet-kleincellige longkanker37 studies
- Metastatische kanker31 studies
- Kanker (alle vormen)30 studies
- Colorectale kanker29 studies
- Eierstokkanker29 studies
- Multipel myeloom24 studies
- Prostaatkanker22 studies
- Hartfalen22 studies
- Aldermeesklierkanker22 studies
- Longkanker20 studies
- Endometriumkanker20 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.